연구성과로 돌아가기
2023 연구자 정보 (1051 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Cha, E. (Cha, E) |
Genentech Inc, San Francisco, CA USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Chen, M. (Chen, M) |
Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Cheng, A-L (Cheng, AL) |
Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan Natl Taiwan Univ Hosp, Taipei, Taiwan |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Cho, Hee Jin (Cho, HJ) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea Samsung Med Ctr, Precis Med Res Inst, Seoul 06351, South Korea Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu 41566, South Korea Kyungpook Natl Univ, Sch Convergence, Dept Biomed Convergence Sci & Technol, Daegu, South Korea |
|
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 18.3] Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern [JCR상위 28.4] Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response [JCR상위 14.0] The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling [JCR상위 1.2] Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling [JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma |
SCIE | 1.2 |
ONCOLOGY MULTIDISCIPLINARY SCIENCES MEDICINE, RESEARCH & EXPERIMENTAL CELL BIOLOGY;ONCOLOGY GENETICS & HEREDITY |
hc111.kim@samsung.com;shty1@daum.net; san_0729@naver.com;teiroa83@knu.ac.kr; hyosong77@yuhs.ac; nsnam@skku.edu;leej7@ccf.org; leej7@ccf.org; nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk; |
||
|
Chow, P. (Chow, P) |
Natl Canc Ctr Singapore, Singapur, Singapore Duke NUS Med Sch, Singapur, Singapore |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Hack, S. P. (Hack, SP) |
Genentech Inc, San Francisco, CA USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Heo, J. (Heo, J) |
Pusan Natl Univ, Coll Med, Busan, South Korea Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Hsieh, D. (Hsieh, D) |
UT Southwestern Med Ctr, Dallas, TX USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Kang, Won Ki (Kang, WK) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea |
|
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer | SCIE | 68.8 | ONCOLOGY | hc111.kim@samsung.com;shty1@daum.net; | ||
|
Kaseb, A. (Kaseb, A) |
MD Anderson Canc Ctr, Houston, TX USA |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Kim, Hee Cheol (Kim, HC) |
교신저자 | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 06351, South Korea |
|
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer | SCIE | 68.8 | ONCOLOGY | hc111.kim@samsung.com;shty1@daum.net; | |
|
Kim, Kyoung-Mee (Kim, KM) |
Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu 41566, South Korea Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul 06351, South Korea Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul, South Korea |
|
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 58.5] A standardized pathology report for gastric cancer: 2nd edition [JCR상위 34.6] A Standardized Pathology Report for Gastric Cancer: 2nd Edition |
SCIE ESCI |
34.6 |
ONCOLOGY PATHOLOGY GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY |
hc111.kim@samsung.com;shty1@daum.net; hakjjang@catholic.ac.kr;meeyon@yonsei.ac.kr; |
||
|
Kim, Seung Tae (Kim, ST) |
교신저자 |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 06351, South Korea Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea |
E-4164-2012 KIM, SEONG |
|
[JCR상위 68.8] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer [JCR상위 28.4] Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022) |
SCIE | 28.4 | ONCOLOGY | hc111.kim@samsung.com;shty1@daum.net; | |
|
Kudo, M. (Kudo, M) |
Kindai Univ, Osaka, Japan |
AAA-9744-2019 Kudo, Masatoshi |
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY | |||
|
Lee, H. C. (Lee, HC) |
Univ Ulsan, Asan Med Ctr, Seoul, South Korea |
|
|
[JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | SCIE | 68.8 | ONCOLOGY |
페이지 이동: